Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer   Janku Filip   Falchook Gerald   Jackson Tiffiny   Fu Siqing   Naing Aung   Tsimberidou Apostalia   Moulder Stacy   Hong David   Yang Hui   Piha-Paul Sarina   Atkins Johnique   Garcia-Manero Guillermo   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 495-501

Springer Publishing Company

Access to resources Recommend Favorite

A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells

By        

Oncology Reports, Vol. 27, Iss. 3, 2012-01 ,pp. : 867-872

Spandidos Publications

Access to resources Recommend Favorite

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models

By Grossman Rachel   Brastianos Harry   Blakeley Jaishri   Mangraviti Antonella   Lal Bachchu   Zadnik Patti   Hwang Lee   Wicks Robert   Goodwin Rory   Brem Henry   Tyler Betty  

Journal of Neuro-Oncology, Vol. 116, Iss. 1, 2014-01 ,pp. : 59-65

Springer Publishing Company

Access to resources Recommend Favorite

Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect

By Kasuya Kazuhiko   Nagakawa Yuichi   Suzuki Minako   Tanaka Hiroaki   Ohta Hiroshi   Itoi Takao   Tsuchida Akihiko  

Experimental and Therapeutic Medicine, Vol. 2, Iss. 6, 2011-11 ,pp. : 1047-1052

Spandidos Publications

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite